[Remote] Manager, Program Management (PMO) at Abata Therapeutics

Remote

Apply Now

Not SpecifiedCompensation

N/AExperience Level

N/AJob Type

Not SpecifiedVisa

N/AIndustries

Requirements

Bachelor’s degree in life sciences, pharmacy, chemistry, or related field
Minimum 5 years total work experience with 2 years of project management experience in biotech or pharma, preferably with cross-functional teams
At least 2 years’ hands-on Smartsheet experience; Smartsheet Core Product Certification or equivalent desirable
Proficiency in project management tools (Smartsheet, ThinkCell, PowerPoint, Excel, SharePoint, Office Timeline Pro, MS Project, OnePager)
Experience with Smartsheet premium apps such as Control Center, Data Shuttle, Dynamic View, Resource Management preferred
PMP or CAPM certification preferred
Knowledge of biotech processes, scientific terminology, and drug development concepts
Strong organizational, communication, and problem-solving skills

Responsibilities

Support evaluation, implementation, and use of project management tools (especially Smartsheet); define methodologies and reporting frameworks
Develop and maintain integrated program timelines across multiple projects
Create and manage templates, dashboards, and visual reports for teams and leadership
Facilitate meetings, schedule attendees, and capture minutes
Build custom PMO solutions: perform gap analyses and develop strategic recommendations
Design and maintain Smartsheet sheets, reports, dashboards, and forms
Implement Smartsheet workflows and automations, coordinate improvements with stakeholders
Provide executive- and task-level project reporting
Track risk, quality, and performance metrics
Troubleshoot and enhance PMO solutions, support system updates and new capabilities
Demonstrate critical thinking and initiative to improve PM practices

Skills

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free